A brief review of the management of platinum-resistant–platinum-refractory ovarian cancer

Opportunities in immunotherapy of ovarian cancer

(2016) G. Coukos et al.   ANNALS OF ONCOLOGY

PARP inhibitors: the race is on

(2016) Jessica S Brown et al.   BRITISH JOURNAL OF CANCER

Cancer statistics, 2016

(2016) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology

(2016) Robert J. Morgan et al.   Journal of the National Comprehensive Cancer Network

FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy

(2015) G. Kim et al.   CLINICAL CANCER RESEARCH

Current state of biomarkers in ovarian cancer prognosis

(2015) Katrina K Au et al.   Future Oncology

Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer

(2015) Junzo Hamanishi et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial

(2014) Eric Pujade-Lauraine et al.   JOURNAL OF CLINICAL ONCOLOGY

Ovarian cancer

(2014) Gordon C Jayson et al.   LANCET

The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes

(2014) Elias Jabbour et al.   LEUKEMIA & LYMPHOMA

The role of the fallopian tube in the origin of ovarian cancer

(2013) Britt K. Erickson et al.   AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY

Ovarian cancer evolution through stochastic genome alterations: defining the genomic role in ovarian cancer

(2013) Batoul Y. Abdallah et al.   Systems Biology in Reproductive Medicine

Recurrent epithelial ovarian cancer and hormone therapy

(2013) Yoshihito Yokoyama   World Journal of Clinical Cases

The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy

(2012) L. C. Hanker et al.   ANNALS OF ONCOLOGY

From the “Silent Killer” to the “Whispering Disease”: Ovarian Cancer and the Uses of Metaphor

(2012) Patricia Jasen   MEDICAL HISTORY

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival Trends in Platinum-Resistant Patients with Advanced Ovarian, Fallopian or Peritoneal Cancer Treated with First-Line Paclitaxel/Platinum Chemotherapy: The Impact of Novel Agents

(2012) Aristotle Bamias et al.   ONCOLOGY

Clinical Trials in Recurrent Ovarian Cancer

(2011) Michael Friedlander et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer

(2011) Robert A. Burger et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Phase 3 Trial of Bevacizumab in Ovarian Cancer

(2011) Timothy J. Perren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Identifying symptoms of ovarian cancer: a qualitative and quantitative study

(2008) CR Bankhead et al.   BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY

Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma

(2008) Hiroaki Itamochi et al.   CANCER SCIENCE

Management of partially platinum-sensitive relapsed ovarian cancer

(2008) Stanley B. Kaye   EJC SUPPLEMENTS

Weekly topotecan for recurrent platinum resistant ovarian cancer

(2007) Fadi Abushahin et al.   GYNECOLOGIC ONCOLOGY

Tumor Residual After Surgical Cytoreduction in Prediction of Clinical Outcome in Stage IV Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study

(2007) William E. Winter et al.   JOURNAL OF CLINICAL ONCOLOGY